Biceltis 440 mg Injection
  1. Home
  2. Pharma Products
  3. Cipla Ltd
  4. Biceltis 440 mg Injection

Biceltis 440 mg Injection

Biceltis 440 mg Injection contains trastuzumab 440 mg, a monoclonal antibody used mainly for HER2-positive breast and stomach cancers. It is administered by intravenous infusion under the supervision of a qualified healthcare professional. Trastuzumab targets the HER2 protein and helps inhibit the growth of HER2-positive cancer cells.

BUY NOW

Category

Biceltis 440 mg Injection is used in specific treatment regimens for HER2-positive breast cancer and HER2-positive gastric cancer. Trastuzumab binds to the HER2 receptor and interferes with signals that promote cancer-cell growth. The medicine may be used alone or in combination with other anticancer treatments depending on the clinical condition and treatment protocol. The dose and treatment schedule are determined by the oncologist, with appropriate monitoring during therapy.

Technical Specification

Specification Details
Active Ingredient Trastuzumab
Strength 440 mg
Dosage Form Lyophilized Powder for Injection
Route of Administration Intravenous Infusion
Pack Size 1 Vial
Manufacturer Cipla Ltd

Product Also Known As

Biceltis 440 mg Injection, Biceltis 440 Injection, Biceltis Trastuzumab Injection, Trastuzumab 440 mg Injection, Trastuzumab HER2 Cancer Injection, Trastuzumab Monoclonal Antibody Injection